Welcome to our dedicated page for Charming Medical SEC filings (Ticker: MCTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Charming Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Charming Medical's regulatory disclosures and financial reporting.
Charming Medical Limited is a British Virgin Islands holding company whose wellness services business is conducted entirely through operating subsidiaries in Hong Kong. It reports in U.S. dollars while transacting in Hong Kong dollars, which have long been pegged at approximately HK$7.80 per US$1.00.
The company previously used a dual-class share structure. As of March 31, 2026, 15,178,000 Class A Ordinary Shares and 2,000,000 super-voting Class B Ordinary Shares were outstanding. On July 21, 2026 Ms. Kit Wong agreed to surrender all Class B shares for cancellation, leaving 15,178,000 ordinary shares outstanding, of which she holds 10,350,360, or 68.19% of voting power.
Management emphasizes extensive legal and regulatory risk tied to Hong Kong’s evolving relationship with mainland China. Counsel currently view PRC data-security, cybersecurity and CSRC overseas-listing rules as inapplicable, and no PRC or Hong Kong permissions are required, but future changes could restrict cash transfers, overseas offerings or Nasdaq trading and could severely impact share value.
Charming Medical Limited has adopted several corporate governance enhancements. Its board approved a one-year lock-up under which CEO and Chair Kit Wong agreed not to sell, transfer or hedge any Class A ordinary shares or related securities, subject to limited customary exceptions. The company has also elected to stop using Nasdaq corporate governance exemptions available to foreign private issuers and instead follow all Nasdaq rules applicable to U.S. domestic issuers, including board and committee composition, shareholder approval for certain issuances, and proxy and annual meeting requirements.
Ms. Wong has irrevocably undertaken to surrender, for no consideration, all 2,000,000 Class B ordinary shares, each carrying twenty votes. Her Class A and Class B holdings previously represented approximately 91.25% of voting power after the IPO. After cancellation of the Class B shares, the dual-class share structure will be abolished, leaving 15,178,000 Ordinary Shares outstanding, with one vote per share. Ms. Wong will hold 10,350,360 Ordinary Shares, or about 68.19% of the shares and voting power. The company will still qualify as a foreign private issuer for Exchange Act reporting, and it cautions that there is no assurance trading in its ordinary shares will resume, that it will maintain its Nasdaq listing, or regarding the timing, completion or outcome of these measures.
Charming Medical Limited reported board changes, with independent director Matthew Mo Kan Tsui resigning effective April 27, 2026, to pursue other business commitments, with no disagreement on operations, policies, or procedures.
On May 2, 2026, the board appointed Mei CaiUS$50,000. The board determined she is an independent director under U.S. SEC and Nasdaq rules and qualifies as an audit committee financial expert. Ms. Cai was named chairman of the Audit Committee and a member of the Compensation and Nominating Committees.
Charming Medical Limited appointed Matthew Mo Kan Tsui as a non-employee, independent director effective April 2, 2026, with annual compensation of HK$384,000. He will serve until a successor is elected and qualified or an earlier departure.
The Board determined that Mr. Tsui is an independent director under U.S. SEC and Nasdaq rules and that he qualifies as an “audit committee financial expert” with required financial sophistication. He will chair the Audit Committee and sit on the Compensation and Nominating Committees. Mr. Tsui brings over 20 years of experience in accounting, corporate finance, capital markets, and audit, including roles at KPMG and listed Hong Kong companies, and holds professional CPA memberships and an accounting and finance degree.
Charming Medical Limited reports unaudited results for the six months ended September 30, 2025, showing a swing to loss and liquidity pressure. Revenue fell to $2,159,935 from $2,958,508 a year earlier as beauty, wellness and postpartum services declined, partly offset by product sales and new franchise income.
The company recorded a net loss of $72,978 versus net income of $468,817 in 2024, with higher professional fees and lower advertising spend. At September 30, 2025, total assets were $5,454,979 and shareholders’ equity was $357,972, against total liabilities of $5,097,007, including contract liabilities of $3,717,923.
Charming ended the period with cash and cash equivalents of $1,774,240, certificates of deposit of $398,687 and trading securities of $513,546, but disclosed a working capital deficit of $2,063,824. Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on operations, its controlling shareholder, financial institutions and investors for funding.
Charming Medical Limited reported a change in its board leadership. On March 27, 2026, independent director Ms. Josephine Yan Yeung resigned from the board to pursue other business commitments. The company stated her resignation was not due to any disagreement with its operations, policies, or procedures.
The board accepted and approved Ms. Yeung’s resignation on the same day. Charming Medical is actively identifying a suitable replacement and expects to fill the independent director vacancy by April 2, 2026, aiming to maintain continuity in its board oversight.
Kit Wong has filed a Schedule 13D disclosing a controlling stake in Charming Medical Ltd. She beneficially owns 10,350,360 Class A ordinary shares and 2,000,000 Class B ordinary shares, giving her approximately 91.65% of the company’s aggregate voting power.
The Class A shares carry one vote per share and the Class B shares carry twenty votes per share, based on 14,938,000 Class A and 2,000,000 Class B shares outstanding. Wong, the company’s CEO, director, and board chair, notes she is a pre-IPO shareholder and holds the securities with the intent to exercise control, and reports no transactions in the past sixty days and no specific additional plans beyond this control position.
Charming Medical Ltd director Yu Shu Tai Victor has filed an initial statement of beneficial ownership on Form 3. The filing does not report any insider stock transactions or list any derivative positions for this director at Charming Medical Ltd.
Charming Medical Ltd director and Chief Executive Officer Wong Kit Christine has filed an initial statement of ownership. She reports holding 10,350,360 Class A ordinary shares and 2,000,000 Class B ordinary shares, each with a par value of US$0.0001 per share.
These positions are reported as direct ownership, and the filing does not show any new purchases or sales, only the share balances following the reporting date.
Charming Medical Ltd filed an initial insider ownership report for its Chief Financial Officer, Cheung Ching Man